Key Details
Price
$40.37Annual ROE
-9.67%Beta
0.16Events Calendar
Next earnings date:
Jan 31, 2025Recent quarterly earnings:
Nov 08, 2024Recent annual earnings:
Nov 08, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Dec 07, 2000Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SurModics (SRDX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to earnings of $0.53 per share a year ago.
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
SurModics (SRDX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Although the revenue and EPS for SurModics (SRDX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
SurModics (SRDX) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to earnings of $0.52 per share a year ago.
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Surmodics, Inc . ( Nasdaq : SRDX ), relating to its proposed sale to GTCR LLC. Under the terms of the agreement, Surmodics, Inc. shareholders will receive $43.00 in cash per share of Surmodics stock they own.
FAQ
- What is the primary business of Surmodics?
- What is the ticker symbol for Surmodics?
- Does Surmodics pay dividends?
- What sector is Surmodics in?
- What industry is Surmodics in?
- What country is Surmodics based in?
- When did Surmodics go public?
- Is Surmodics in the S&P 500?
- Is Surmodics in the NASDAQ 100?
- Is Surmodics in the Dow Jones?
- When was Surmodics's last earnings report?
- When does Surmodics report earnings?
- Should I buy Surmodics stock now?